Modulatory efficacy of bone metabolism and safety of denosumab versus zoledronic acid in the treatment of bone and joint osteoporosis in elderly men
Frontiers in Pharmacology · 23.10.2025 · 16
DOI: 10.3389/fphar.2025.1666421 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 23.10.2025. Verfasst von Jing He und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopedics, Sheyang County People's Hospital, Yancheng, China. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objective
This study aimed to compare the clinical efficacy and safety of denosumab versus zoledronic acid (ZA) in the treatment of osteoporosis in elderly male patients, with the goal of optimizing therapeutic strategies for this population.
Methods
A retrospective analysis was conducted on 89 elderly male osteoporosis patients treated at Sheyang County People’s Hospital from March 2023 to March 2024. Patients were allocated to two treatment arms based on the treatment regimen they received: the denosumab group (n = 49) and the ZA group (n = 40). Adverse drug reactions (e.g., myalgia, flu-like symptoms, and back pain) were recorded, and changes in bone metabolism markers and bone mineral density (BMD) at the lumbar spine (L1-L4), femoral neck, and total hip were evaluated after 1 year of treatment.
Results
After 1 year of treatment, BMD of lumbar spine significantly increased in both groups (P < 0.05), with the denosumab group showing a greater improvement (0.41 ± 0.68 vs. 0.14 ± 0.86, P = 0.037). In contrast, the ZA group demonstrated superior efficacy in BMD of femoral neck (P = 0.011) and total hip (P = 0.029). Adverse reactions occurred in 15 patients: 2 in the denosumab group (muscle pain) and 13 in the ZA group (10 flu-like symptoms, 2 muscle pain, and 1 back pain). The incidence of flu-like symptoms was significantly higher in the ZA group (32.5% vs. 0%, P < 0.001).
Conclusion
Denosumab demonstrated superior efficacy in reducing fracture risk at the lumbar spine, while ZA showed greater protective effects at the hip. Although both agents significantly improved bone metabolic parameters, denosumab exhibited a more favorable safety profile in clinical application.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Orthopedics, Sheyang County People's Hospital, Yancheng, China.
- Shanghai Jiao Tong University School of Medicine, Shanghai, China.
- Key Laboratory of Neuroregeneration of Jiangsu and Ministry of Education, Coinnovation Center of Neuroregeneration, Medical School, Nantong University, Nantong, China.
Zitieren
APA
He, J., Mao, Y., Gong, W., Zhu, H., Xiang, P., Wang, S., & Dai, X. (2025). Modulatory efficacy of bone metabolism and safety of denosumab versus zoledronic acid in the treatment of bone and joint osteoporosis in elderly men. Frontiers in Pharmacology, 16. https://doi.org/10.3389/fphar.2025.1666421
Vancouver
He J, Mao Y, Gong W, Zhu H, Xiang P, Wang S, et al. Modulatory efficacy of bone metabolism and safety of denosumab versus zoledronic acid in the treatment of bone and joint osteoporosis in elderly men. Frontiers in Pharmacology. 2025;16. doi:10.3389/fphar.2025.1666421
BibTeX
@article{He2025,
author = {He, Jing and Mao, Yuhui and Gong, Wanran and Zhu, Haitao and Xiang, Peng and Wang, Shui and Dai, Xiaofeng},
title = {Modulatory efficacy of bone metabolism and safety of denosumab versus zoledronic acid in the treatment of bone and joint osteoporosis in elderly men},
journal = {Frontiers in Pharmacology},
year = {2025},
volume = {16},
doi = {10.3389/fphar.2025.1666421}
}
EUVIMED